Abstract: Provided herein are novel panels of biomarkers for the detection and diagnosis of lung adenocarcinoma, and methods and kits for detecting these biomarkers in samples of individuals suspected of having the disease. Also provided are methods of monitoring the progression of lung adenocarcinoma and methods of monitoring the efficacy of a treatment.

Abstract: Provided herein are novel panels of biomarkers for the detection and diagnosis of lung adenocarcinoma, and methods and kits for detecting these biomarkers in samples of individuals suspected of having the disease. Also provided are methods of monitoring the progression of lung adenocarcinoma and methods of monitoring the efficacy of a treatment.

Abstract: Provided herein are multiple antigen detection (MAD) assays and reagents for performing such assays. MAD assay embodiments are useful for identifying proximal antigens in a sample (e.g., antigens existing in a complex), and are performed by contacting a sample with two or more hybrids, where each hybrid comprises a nucleic acid and a binding partner that specifically binds to an antigen. In these embodiments, the hybrid nucleic acids hybridize to one another when the hybrids bind to proximal antigens, and the hybridization product then is detected, often by a polymerase chain reaction (PCR) process or a nucleic acid binding agent comprising a detectable label. MAD assays and reagents are applicable to antigen detection in situ, chromatin immunoprecipitation and genomic sequencing, detection of proximal intramolecular regions in an antigen, detecting antigen multimerization, diagnostics and therapeutics. Also provided are kits for conducting MAD applications.